A network meta-analysis of antibiotics for treatment of hospitalised patients with suspected or proven meticillin-resistant Staphylococcus aureus infection

International Journal of Antimicrobial Agents

Volumn 40, Issue 6, 2012, Pages 479-495

  Bally, Michèle ^a,b   Dendukuri, Nandini ^a,c   Sinclair, Alison ^c   Ahern, Stéphane P ^b,d   Poisson, Michel ^b,e   Brophy, James ^c,f  

^a MCGILL UNIVERSITY   (Canada)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

^c ROYAL VICTORIA HOSPITAL   (Canada)

^d MAISONNEUVE ROSEMONT HOSPITAL   (Canada)

^e CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^f MCGILL UNIVERSITY   (Canada)

Author keywords

Comparative effectiveness and safety; Meticillin resistant Staphylococcus aureus; Network meta analysis; Systematic review; Vancomycin

Indexed keywords

ANTIBIOTIC AGENT; AZTREONAM; CEFTAROLINE; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; LINEZOLID; PENICILLIN G; TEICOPLANIN; TELAVANCIN; TIGECYCLINE; VANCOMYCIN;

ADULT; ANTIBIOTIC THERAPY; ARTIFICIAL VENTILATION; CAUSE OF DEATH; CLINICAL EFFECTIVENESS; COMPARATIVE EFFECTIVENESS; DIABETIC PATIENT; DRUG SAFETY; FEMALE; HOSPITAL ACQUIRED PNEUMONIA; HOSPITAL PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SKIN INFECTION; SOFT TISSUE INFECTION; SYSTEMATIC REVIEW; VENTILATOR ASSOCIATED PNEUMONIA;

EID: 84869498650     PISSN: 09248579     EISSN: 18727913     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2012.08.004     Document Type: Short Survey

References (119)

1. H.F. Chambers, and F.R. DeLeo Waves of resistance: Staphylococcus aureus in the antibiotic era Nat Rev Microbiol 7 2009 629 641
2. R. Köck, K. Becker, B. Cookson, J.E. van Gemert-Pijnen, S. Harbarth, and J. Kluytmans Methicillin-resistant Staphylococcus aureus (MRSA): burden of disease and control challenges in Europe Euro Surveill 15 2010 19688
3. R. Jones Microbial etiologies of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia Clin Infect Dis 51 Suppl. 1 2010 S81 S87
4. G. Moet, R. Jones, D. Biedenbach, M. Stilwell, and T. Fritsche Contemporary causes of skin and soft tissue infections in North America, Latin America, and Europe: report from the SENTRY Antimicrobial Surveillance Program (1998-2004) Diagn Microbiol Infect Dis 57 2007 7 13 (Pubitemid 44908825)
5. G. Sakoulas, and J.R. Moellering Increasing antibiotic resistance among methicillin-resistant Staphylococcus aureus strains Clin Infect Dis 46 Suppl. 5 2008 S360 S367
6. C. Liu, A. Bayer, S.E. Cosgrove, R.S. Daum, S.K. Fridkin, and R.J. Gorwitz Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary Clin Infect Dis 52 2011 285 292
7. G. Steinkraus, R. White, and L. Friedrich Vancomycin MIC creep in non-vancomycin-intermediate Staphylococcus aureus (VISA), vancomycin-susceptible clinical methicillin-resistant S. aureus (MRSA) blood isolates from 2001-05 J Antimicrob Chemother 60 2007 788 794 (Pubitemid 47434257)
8. J.L. Wang, J.T. Wang, W.H. Sheng, Y.C. Chen, and S.C. Chang Nosocomial methicillin-resistant Staphylococcus aureus (MRSA) bacteremia in Taiwan: mortality analyses and the impact of vancomycin, MIC = 2 mg/L, by the broth microdilution method BMC Infect Dis 10 2010 159
9. S.J. van Hal, T.P. Lodise, and D.L. Paterson The clinical significance of vancomycin minimum inhibitory concentration in Staphylococcus aureus infections: a systematic review and meta-analysis Clin Infect Dis 54 2012 755 771
10. B. Edwards, K. Milne, T. Lawes, I. Cook, A. Robb, and I.M. Gould Is vancomycin MIC 'creep' method dependent? Analysis of methicillin-resistant Staphylococcus aureus susceptibility trends in blood isolates from North East Scotland from 2006 to 2010 J Clin Microbiol 50 2012 318 325
11. B.P. Howden, J.K. Davies, P.D.R. Johnson, T.P. Stinear, and M.L. Grayson Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection, and clinical implications Clin Microbiol Rev 23 2010 99 139
12. R. Khatib, J. Jose, A. Musta, M. Sharma, M.G. Fakih, and L.B. Johnson Relevance of vancomycin-intermediate susceptibility and heteroresistance in methicillin-resistant Staphylococcus aureus bacteraemia J Antimicrob Chemother 66 2011 1594 1599
13. S.J. van Hal, and D.L. Paterson Systematic review and meta-analysis of the significance of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates Antimicrob Agents Chemother 55 2011 405 410
14. D.M. Caldwell, A.E. Ades, and J.P. Higgins Simultaneous comparison of multiple treatments: combining direct and indirect evidence BMJ 331 2005 897 900 (Pubitemid 41502718)
15. J.P. Jansen, B. Crawford, G. Bergman, and W. Stam Bayesian meta-analysis of multiple treatment comparisons: an introduction to mixed treatment comparisons Value Health 11 2008 956 964
16. G. Lu, and A.E. Ades Combination of direct and indirect evidence in mixed treatment comparisons Stat Med 23 2004 3105 3124 (Pubitemid 39334902)
17. DRUGDEX® System. Internet database. Version 5.1. Greenwood Village, CO: Thomson Reuters (Healthcare) Inc.
18. Durata Therapeutics initiates phase 3 study of dalbavancin for the treatment of acute bacterial skin and skin structure infections. Medical News Today 20 Apr 2011. http://www.medicalnewstoday.com/releases/222976.php [accessed 19.12.11].
19. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research. Guidance for industry. Uncomplicated and complicated skin and skin structure infections - developing antimicrobial drugs for treatment. July 1998.
20. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research. Guidance for industry. Acute bacterial skin and skin structure infections - developing drugs for treatment. August 2010.
21. American Thoracic Society (ATS) Infectious Diseases Society of America (IDSA) Guidelines for the management of adults with hospital-acquired, ventilator- associated and healthcare-associated pneumonia Am J Respir Crit Care Med 171 2005 388 416
22. R.G. Masterton, A. Galloway, G. French, M. Street, J. Armstrong, and E. Brown Guidelines for the management of hospital-acquired pneumonia in the UK: report of the Working Party on Hospital-Acquired Pneumonia of the British Society for Antimicrobial Chemotherapy J Antimicrob Chemother 62 2008 5 34 (Pubitemid 351865870)
23. M.Z. David, and R.S. Daum Community-associated methicillin-resistant Staphylococcus aureus: epidemiology and clinical consequences of an emerging epidemic Clin Microbiol Rev 23 2010 616 687
24. J.A. Otter, and G.L. French Molecular epidemiology of community-associated meticillin-resistant Staphylococcus aureus in Europe Lancet Infect Dis 10 2010 227 239
25. R.M. Klevens, M.A. Morrison, J. Nadle, J. Nadle, S. Petit, and K. Gershman Invasive methicillin-resistant Staphylococcus aureus infections in the United States JAMA 298 2007 1763 1771 (Pubitemid 47598444)
26. H.W. Boucher, and G.R. Corey Epidemiology of methicillin-resistant Staphylococcus aureus Clin Infect Dis 46 Suppl. 5 2008 S344 S349
27. F.R. DeLeo, M. Otto, B.N. Kreiswirth, and H.F. Chambers Community-associated meticillin-resistant Staphylococcus aureus Lancet 375 2010 1557 1568
28. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research. Guidance for industry. Hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia - developing drugs for treatment. November 2010.
29. European Medicines Agency. Guideline on the evaluation of medicinal products indicated for treatment of bacterial infections. 15 December 2011.
30. G.R. Corey, and M.E. Stryjewski New rules for clinical trials of patients with acute bacterial skin and skin-structure infections: do not let the perfect be the enemy of the good Clin Infect Dis 52 Suppl. 7 2011 S469 S476
31. K. Laessig End points in hospital-acquired pneumonia and/or ventilator-associated pneumonia clinical trials: Food and Drug Administration perspective Clin Infect Dis 51 Suppl. 1 2010 S117 S119
32. B. Spellberg, and G. Talbot Recommended design features of future clinical trials of antibacterial agents for hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia Clin Infect Dis 51 Suppl. 1 2010 S150 S170
33. Canadian Agency for Drugs and Technology in Health (CADTH) Common drug review: annotated clinical review report 2008 CADTH Ottawa, ON, Canada
34. A. O'Connor The need for improved access to FDA reviews JAMA 302 2009 191 193
35. K. Rising, P. Bacchetti, and L. Bero Reporting bias in drug trials submitted to the Food and Drug Administration: a review of publication and presentation PLoS Med 5 2008 e217
36. T. Jefferson, M.A. Jones, P. Doshi, C.B. Del Mar, C.J. Heneghan, and R. Hama Neuraminidase inhibitors for preventing and treating influenza in healthy adults and children Cochrane Database Syst Rev 1 2012 CD008965
37. T. Lasserson, and D. Tovey Neuraminidase inhibitors for influenza: methods change, principles don't Cochrane Database Syst Rev 2 2012 ED000038
38. A. Liberati, D.G. Altman, J. Tetzlaff, C. Mulrow, P.C. Gotzsche, and J.P. Ioannidis The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration BMJ 339 2009 b2700
39. J. Higgins, D. Altman, and J. Sterne Assessing risk of bias in included studies J. Higgins, S. Green, Cochrane handbook for systematic reviews of interventions 2011 John Wiley & Sons, Ltd. Chichester, UK [Chapter 8]
40. D.N. Gilbert, R.C. Moellering, G.M. Eliopoulis, H.F. Chambers, and M.S. Saag The Sanford guide to antimicrobial therapy 2011 41st ed. 2011 Antimicrobial Therapy, Inc. Sperryville, VA
41. J. Edelsberg, A. Berger, D.J. Weber, R. Mallick, A. Kuznik, and G. Oster Clinical and economic consequences of failure of initial antibiotic therapy for hospitalized patients with complicated skin and skin-structure infections Infect Control Hosp Epidemiol 29 2008 160 169 (Pubitemid 351269212)
42. B.A. Lipsky, K.M.F. Itani, J.A. Weigelt, W. Joseph, C.M. Paap, and A. Reisman The role of diabetes mellitus in the treatment of skin and skin structure infections caused by methicillin-resistant Staphylococcus aureus: results from three randomized controlled trials Int J Infect Dis 15 2011 e140 e146
43. M.S. Niederman Hospital-acquired pneumonia, health care-associated pneumonia, ventilator-associated pneumonia, and ventilator-associated tracheobronchitis: definitions and challenges in trial design Clin Infect Dis 51 Suppl. 1 2010 S12 S17
44. L. Napolitano Use of severity scoring and stratification factors in clinical trials of hospital-acquired and ventilator-associated pneumonia Clin Infect Dis 51 Suppl. 1 2010 S67 S80
45. P. Ambrose, S. Bhavnani, E. Ellis-Grosse, and G. Drusano Pharmacokinetic-pharmacodynamic considerations in the design of hospital-acquired or ventilator-associated bacterial pneumonia studies: look before you leap! Clin Infect Dis 51 Suppl. 1 2010 S103 S110
46. G. Salanti, A.E. Ades, and J.P.A. Ioannidis Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial J Clin Epidemiol 64 2011 163 171
47. J.P. Jansen, C.H. Schmid, and G. Salanti Directed acyclic graphs can help understand bias in indirect and mixed treatment comparisons J Clin Epidemiol 65 2012 798 807
48. N.J. Cooper, A.J. Sutton, D. Morris, A.E. Ades, and N.J. Welton Addressing between-study heterogeneity and inconsistency in mixed treatment comparisons: application to stroke prevention treatments in individuals with non-rheumatic atrial fibrillation Stat Med 28 2009 1861 1881
49. Dias S, Sutton AJ, Welton NJ, Ades AE. NICE Decision Support Unit (DSU) technical support document 2: a generalised linear modelling framework for pairwise and network meta-analysis of randomised controlled trials. August 2011. http://www.nicedsu.org.uk/Evidence-Synthesis-TSD-series%282391675%29.htm [accessed 14.10.11].
50. Dias S, Sutton A, Welton N, Ades A. NICE Decision Support Unit (DSU) technical support document 3: heterogeneity: subgroups, meta-regression, bias and bias-adjustment. September 2011. http://www.nicedsu.org.uk/Evidence- Synthesis-TSD-series%282391675%29.htm [accessed 17.10.11].
51. A. Gelman Prior distributions for variance parameters in hierarchical models Bayesian Anal 1 2006 515 533
52. D.J. Spiegelhalter, K.R. Abrams, and J.P. Myles Prior distributions Bayesian approaches to clinical trials and health-care evaluation 2004 John Wiley & Sons, Ltd. Chichester, UK p. 139-77
53. D. Spiegelhalter, N. Best, B. Carlin, and A. van der Linde Bayesian measures of model complexity and fit J R Statist Soc B 64 2002 1 34
54. H. Wacha, and H. Forster Comparison of quinupristin/dalfopristin with standard therapies for the treatment of complicated skin and soft tissue infections due to Gram-positive pathogens: results of two open, randomized multicenter studies Chemotherapie J 9 2000 63 68 [in German] (Pubitemid 35012677)
55. S.A. Grudinina, M.M. Zubkov, L.A. Krotova, I.U.P. Kurdiukova, M.A. Kutsenko, and V.F. Marinin Comparison of linezolid and vancomycin in nosocomial pneumonia: results of the multicenter double-blind study Antibiot Khimioter 47 2002 12 17 [in Russian] (Pubitemid 135747424)
56. Y.C. Chuang, C.M. Chang, S. Aradhya, B. Nagari, V. Pai, and N. Dartois Efficacy and safety of tigecycline monotherapy compared with vancomycin-aztreonam in the treatment of complicated skin and skin structure infections in patients from India and Taiwan J Microbiol Immunol Infect 44 2011 116 124
57. D. Luke, D. Hewlett, V. Verna Welch, R. Chambers, and D.B. Huang Incidence of intravenous catheter-site complications in patients treated with linezolid or vancomycin for skin infections caused by methicillin-resistant Staphylococcus aureus Hospital Pharmacy 46 2011 427 431
58. M.H. Kollef, J. Rello, S.K. Cammarata, R.V. Croos-Dabrera, and R.G. Wunderink Clinical cure and survival in Gram-positive ventilator-associated pneumonia: retrospective analysis of two double-blind studies comparing linezolid with vancomycin Intensive Care Med 30 2004 388 394 (Pubitemid 38375611)
59. M.E. Stryjewski, W.D. O'Riordan, W.K. Lau, F.D. Pien, L.M. Dunbar, and M. Vallee Telavancin versus standard therapy for treatment of complicated skin and soft-tissue infections due to Gram-positive bacteria Clin Infect Dis 40 2005 1601 1607 (Pubitemid 40720810)
60. E.J. Ellis-Grosse, T. Babinchak, N. Dartois, G. Rose, and E. Loh The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: results of 2 double-blind phase 3 comparison studies with vancomycin-aztreonam Clin Infect Dis 41 Suppl. 5 2005 S341 S353
61. R.G. Wunderink, J. Rello, S.K. Cammarata, R.V. Croos-Dabrera, and M.H. Kollef Linezolid vs vancomycin: analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia Chest 124 2003 1789 1797 (Pubitemid 37433574)
62. S.L. Barriere ATLAS trials: efficacy and safety of telavancin compared with vancomycin for the treatment of skin infections Future Microbiol 5 2010 1765 1773
63. G.R. Corey, M. Wilcox, G.H. Talbot, H.D. Friedland, T. Baculik, and G.W. Witherell Integrated analysis of CANVAS 1 and 2: phase 3, multicenter, randomized, double-blind studies to evaluate the safety and efficacy of ceftaroline versus vancomycin plus aztreonam in complicated skin and skin-structure infection Clin Infect Dis 51 2010 641 650
64. M.L. Corrado Integrated safety summary of CANVAS 1 and 2 trials: phase III, randomized, double-blind studies evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections J Antimicrob Chemother 65 Suppl. 4 2010 iv67 iv71
65. A.T. Freire, V. Melnyk, M.J. Kim, O. Datsenko, O. Dzyublik, and F. Glumcher 311 Study Group. Comparison of tigecycline with imipenem/cilastatin for the treatment of hospital-acquired pneumonia Diagn Microbiol Infect Dis 68 2010 140 151
66. R.L. Nichols, D.R. Graham, S.L. Barriere, A. Rodgers, S.E. Wilson, and M. Zervos Treatment of hospitalized patients with complicated Gram-positive skin and skin structure infections: two randomized, multicentre studies of quinupristin/dalfopristin versus cefazolin, oxacillin or vancomycin J Antimicrob Chemother 44 1999 263 273 (Pubitemid 29389290)
67. P.E. Pertel, B.I. Eisenstein, A.S. Link, B. Donfrid, E.J. Biermann, and P. Bernardo The efficacy and safety of daptomycin vs. vancomycin for the treatment of cellulitis and erysipelas Int J Clin Pract 63 2009 368 375
68. J.N. Sharpe, E.H. Shively, and H.C. Polk Jr. Clinical and economic outcomes of oral linezolid versus intravenous vancomycin in the treatment of MRSA-complicated, lower-extremity skin and soft-tissue infections caused by methicillin-resistant Staphylococcus aureus Am J Surg 189 2005 425 428 (Pubitemid 40488237)
69. K.M.F. Itani, M.S. Dryden, H. Bhattacharyya, M.J. Kunkel, A.M. Baruch, and J.A. Weigelt Efficacy and safety of linezolid versus vancomycin for the treatment of complicated skin and soft-tissue infections proven to be caused by methicillin-resistant Staphylococcus aureus Am J Surg 199 2010 804 816
70. D.F. Lin, Y.Y. Zhang, J.F. Wu, F. Wang, J.C. Zheng, and J.Z. Miao Linezolid for the treatment of infections caused by Gram-positive pathogens in China Int J Antimicrob Agents 32 2008 241 249
71. S. Kohno, K. Yamaguchi, N. Aikawa, Y. Sumiyama, S. Odagiri, and N. Aoki Linezolid versus vancomycin for the treatment of infections caused by methicillin-resistant Staphylococcus aureus in Japan J Antimicrob Chemother 60 2007 1361 1369 (Pubitemid 350168334)
72. J. Weigelt, K. Itani, D. Stevens, W. Lau, M. Dryden, and C. Knirsch Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections Antimicrob Agents Chemother 49 2005 2260 2266 (Pubitemid 40734452)
73. D.L. Stevens, D. Herr, H. Lampiris, J.L. Hunt, D.H. Batts, and B. Hafkin Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections Clin Infect Dis 34 2002 1481 1490 (Pubitemid 34553708)
74. D.E. Katz, K.C. Lindfield, J.N. Steenbergen, D.P. Benziger, K.J. Blackerby, and A.G. Knapp A pilot study of high-dose short duration daptomycin for the treatment of patients with complicated skin and skin structure infections caused by Gram-positive bacteria Int J Clin Pract 62 2008 1455 1464
75. R.D. Arbeit, D. Maki, F.P. Tally, E. Campanaro, and B.I. Eisenstein The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections Clin Infect Dis 38 2004 1673 1681 (Pubitemid 38781657)
76. I. Florescu, M. Beuran, R. Dimov, A. Razbadauskas, M. Bochan, and G. Fichev Efficacy and safety of tigecycline compared with vancomycin or linezolid for treatment of serious infections with methicillin-resistant Staphylococcus aureus or vancomycin-resistant enterococci: a phase 3, multicentre, double-blind, randomized study J Antimicrob Chemother 62 Suppl. 1 2008 i17 i28
77. J. Breedt, J. Teras, J. Gardovskis, F.J. Maritz, T. Vaasna, and D.P. Ross Safety and efficacy of tigecycline in treatment of skin and skin structure infections: results of a double-blind phase 3 comparison study with vancomycin-aztreonam Antimicrob Agents Chemother 49 2005 4658 4666 (Pubitemid 41552597)
78. S. Sacchidanand, R.L. Penn, J.M. Embil, M.E. Campos, D. Curcio, and E. Ellis-Grosse Efficacy and safety of tigecycline monotherapy compared with vancomycin plus aztreonam in patients with complicated skin and skin structure infections: results from a phase 3, randomized, double-blind trial Int J Infect Dis 9 2005 251 261 (Pubitemid 41196869)
79. M.E. Stryjewski, D.R. Graham, S.E. Wilson, W. O'Riordan, D. Young, and A. Lentnek Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections caused by Gram-positive organisms Clin Infect Dis 46 2008 1683 1693 (Pubitemid 351706765)
80. M.E. Stryjewski, V.H. Chu, W.D. O'Riordan, B.L. Warren, L.M. Dunbar, and D.M. Young Telavancin versus standard therapy for treatment of complicated skin and skin structure infections caused by Gram-positive bacteria: FAST 2 study Antimicrob Agents Chemother 50 2006 862 867 (Pubitemid 43327787)
81. G.R. Corey, M.H. Wilcox, G.H. Talbot, D. Thye, D. Friedland, and T. Baculik CANVAS 1: the first phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections J Antimicrob Chemother 65 Suppl. 4 2010 iv41 iv51
82. M.H. Wilcox, G.R. Corey, G.H. Talbot, D. Thye, D. Friedland, and T.C. Baculik CANVAS 2: the second phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections J Antimicrob Chemother 65 Suppl. 4 2010 iv53 iv65
83. G.H. Talbot, D. Thye, A. Das, and Y. Ge Phase 2 study of ceftaroline versus standard therapy in treatment of complicated skin and skin structure infections Antimicrob Agents Chemother 51 2007 3612 3616 (Pubitemid 47519351)
84. R.G. Wunderink, M.S. Niederman, M.H. Kollef, A.F. Shorr, M.J. Kunkel, and A. Baruch Linezolid in methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a randomized, controlled study Clin Infect Dis 54 2012 621 629 and Pfizer Inc. PhRMA Web Synopsis. Protocol A5951001 - 17 November 2010. http://www.phrma.org/ [accessed 25.10.11]
85. R.G. Wunderink, M.H. Mendelson, M.S. Somero, T.C. Fabian, A.K. May, and H. Bhattacharyya Early microbiological response to linezolid vs vancomycin in ventilator-associated pneumonia due to methicillin-resistant Staphylococcus aureus Chest 134 2008 1200 1207
86. R.G. Wunderink, S.K. Cammarata, T.H. Oliphant, M.H. Kollef Linezolid Nosocomial Pneumonia Study Group Continuation of a randomized, double-blind, multicenter study of linezolid versus vancomycin in the treatment of patients with nosocomial pneumonia Clin Ther 25 2003 980 992 (Pubitemid 36459702)
87. E. Rubinstein, S. Cammarata, T. Oliphant, R. Wunderink Linezolid Nosocomial Pneumonia Study Group Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: a randomized, double-blind, multicenter study Clin Infect Dis 32 2001 402 412 (Pubitemid 32173626)
88. E. Rubinstein, T. Lalani, G.R. Corey, Z.A. Kanafani, E.C. Nannini, and M.G. Rocha Telavancin versus vancomycin for hospital-acquired pneumonia due to Gram-positive pathogens Clin Infect Dis 52 2011 31 40
89. J. Fagon, H. Patrick, D.W. Haas, A. Torres, C. Gibert, and W.G. Cheadle Treatment of Gram-positive nosocomial pneumonia. Prospective randomized comparison of quinupristin/dalfopristin versus vancomycin. Nosocomial Pneumonia Group Am J Respir Crit Care Med 161 2000 753 762 (Pubitemid 30171727)
90. G. Salanti, J.P. Higgins, A.E. Ades, and J.P. Ioannidis Evaluation of networks of randomized trials Stat Methods Med Res 17 2008 279 301
91. A.B. Cavalcanti, A.R. Goncalves, C.S. Almeida, D.D.G. Bugano, and E. Silva Teicoplanin versus vancomycin for proven or suspected infection Cochrane Database Syst Rev 6 2010 CD007022
92. Salanti G. Multiple-treatments meta-analysis (MTM). Presenting the results from an MTM analysis. Fit MTM models in WinBUGS. University of Ioannina School of Medicine, Department of Hygiene and Epidemiology. http://www.mtm.uoi. gr/models.html [accessed 07.02.12].
93. Y. Cai, R. Wang, B. Liang, N. Bai, and Y. Liu Systematic review and meta-analysis of the effectiveness and safety of tigecycline for treatment of infectious disease Antimicrob Agents Chemother 55 2011 1162 1172
94. L. Beibei, C. Yun, C. Mengli, B. Nan, Y. Xuhong, and W. Rui Linezolid versus vancomycin for the treatment of Gram-positive bacterial infections: meta-analysis of randomised controlled trials Int J Antimicrob Agents 35 2010 3 12
95. M.E. Falagas, I.I. Siempos, and K.Z. Vardakas Linezolid versus glycopeptide or β-lactam for treatment of Gram-positive bacterial infections: meta-analysis of randomised controlled trials Lancet Infect Dis 8 2008 53 66 (Pubitemid 351620940)
96. E. Tasina, A.B. Haidich, S. Kokkali, and M. Arvanitidou Efficacy and safety of tigecycline for the treatment of infectious diseases: a meta-analysis Lancet Infect Dis 11 2011 834 844
97. D. Yahav, A. Lador, M. Paul, and L. Leibovici Efficacy and safety of tigecycline: a systematic review and meta-analysis J Antimicrob Chemother 66 2011 1963 1971
98. A.C. Kalil, M.H. Murthy, E.D. Hermsen, F.K. Neto, J. Sun, and M.E. Rupp Linezolid versus vancomycin or teicoplanin for nosocomial pneumonia: a systematic review and meta-analysis Crit Care Med 38 2010 1802 1808
99. J.F.S. Logman, J. Stephens, B. Heeg, S. Haider, J. Cappelleri, and D. Nathwani Comparative effectiveness of antibiotics for the treatment of MRSA complicated skin and soft tissue infections Curr Med Res Opin 26 2010 1565 1578
100. T.J. Dodds, and C.I. Hawke Linezolid versus vancomycin for MRSA skin and soft tissue infections (systematic review and meta-analysis) ANZ J Surg 79 2009 629 635
101. I.A. Bliziotis, E. Plessa, G. Peppas, and M.E. Falagas Daptomycin versus other antimicrobial agents for the treatment of skin and soft tissue infections: a meta-analysis Ann Pharmacother 44 2010 97 106
102. M. Bounthavong, and D.I. Hsu Efficacy and safety of linezolid in methicillin-resistant Staphylococcus aureus (MRSA) complicated skin and soft tissue infection (cSSTI): a meta-analysis Curr Med Res Opin 26 2010 407 421
103. A.J. Walkey, M.R. O'Donnell, and R.S. Wiener Linezolid vs glycopeptide antibiotics for the treatment of suspected methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a meta-analysis of randomized controlled trials Chest 139 2010 1148 1155
104. P. Doshi, M. Jones, and T. Jefferson Rethinking credible evidence synthesis BMJ 344 2012 d7898
105. B. Hart, A. Lundh, and L. Bero Effect of reporting bias on meta-analyses of drug trials: reanalysis of meta-analyses BMJ 344 2012 d7202
106. J.J. Kirkham, K.M. Dwan, D.G. Altman, C. Gamble, S. Dodd, and R. Smyth The impact of outcome reporting bias in randomised controlled trials on a cohort of systematic reviews BMJ 340 2010 c365
107. L. Trinquart, A. Abbe, and P. Ravaud Impact of reporting bias in network meta-analysis of antidepressant placebo-controlled trials PLoS ONE 7 2012 e35219
108. Hernán MA, Robins JM. Causal inference. Part I. Chapters 1-10. 2012. http://www.hsph.harvard.edu/faculty/miguel-hernan/files/hernanrobins-v1. 10.13.pdf [accessed 27.02.12].
109. A. Sutton, A.E. Ades, N. Cooper, and K. Abrams Use of indirect and mixed treatment comparisons for technology assessment Pharmacoeconomics 26 9 2008 753 767
110. G. Salanti, V. Marinho, and J.P. Higgins A case study of multiple-treatments meta-analysis demonstrates that covariates should be considered J Clin Epidemiol 62 2009 857 864
111. J.A. Berlin, J. Santanna, C.H. Schmid, L.A. Szczech, and H.I. Feldman Individual patient-versus group-level data meta-regressions for the investigation of treatment effect modifiers: ecological bias rears its ugly head Stat Med 21 2002 371 387 (Pubitemid 34144648)
112. J.G. Muscedere, A. Day, and D.K. Heyland Mortality, attributable mortality, and clinical events as end points for clinical trials of ventilator-associated pneumonia and hospital-acquired pneumonia Clin Infect Dis 51 Suppl. 1 2010 S120 S125
113. New MRSA guidelines highlight a dearth of evidence. Lancet Infect Dis 2011;11:153.
114. V.L. Yu Guidelines for hospital-acquired pneumonia and health-care-associated pneumonia: a vulnerability, a pitfall, and a fatal flaw Lancet Infect Dis 11 2011 248 252
115. D. Lee, and O. Vielemeyer Analysis of overall level of evidence behind Infectious Diseases Society of America practice guidelines Arch Intern Med 171 2011 18 22
116. L. Silvestri, H.K. van Saene, M.A. de la Cal, and A. Gullo Adult hospital and ventilator-associated pneumonia guidelines: eminence- rather than evidence-based Am J Respir Crit Care Med 173 2006 131 133 (Pubitemid 43069800)
117. A.E. Ades ISPOR states its position on network meta-analysis Value Health 14 2011 414 416
118. National Institute for Health and Clinical Excellence (NICE). Guide to methods of technology appraisal. London, UK: NICE; June 2008. http://www.nice.org.uk/media/B52/A7/TAMethodsGuideUpdatedJune2008.pdf [accessed 29.02.12].
119. Wells GA, Sultan SA, Chen L, Khan M, Coyle D. Indirect evidence: indirect treatment comparisons in meta-analysis. Ottawa, ON, Canada: Canadian Agency for Drugs and Technologies in Health; March 2009. http://cadth.ca/media/pdf/H0462- itc-tr-e.pdf [accessed 29.02.12].